Group 1: Financial Management and Risk Control - The significant increase in accounts payable is primarily due to the investment in the "Fujilai (Shandong) Specialty API and Intermediate CMO/CDMO Construction Project" [2] - The company aims to ensure project funding needs while controlling debt scale and financial risks through coordinated project construction and financial management [2] - The company has implemented measures such as credit assessment and collection tracking to optimize accounts receivable management and reduce bad debt risk [3] Group 2: Investment Strategies and Returns - The company utilizes idle funds for entrusted financial management to enhance the efficiency of fund usage and improve returns, without affecting normal operations [3] - The increase in income tax expenses is mainly due to a significant rise in investment income during the current period [3] Group 3: Inventory and Supply Chain Management - The company plans to continuously optimize inventory structure and strengthen market trend analysis to adapt to changes in market demand [3] - The reduction in inventory balance since the beginning of the year has positively impacted profits due to the reversal of inventory impairment provisions [3] Group 4: Project Development and Future Outlook - The "Fujilai (Shandong) Specialty API and Intermediate CMO/CDMO Construction Project" is progressing as per the scheduled timeline, with expected contributions to revenue and profit post-production [5] - The company is focused on enhancing its core competitiveness in the specialty API and intermediate sector to inject new momentum into sustainable development [5] Group 5: Shareholder Communication and Governance - The company emphasizes compliance with legal regulations regarding shareholder reduction plans and will ensure timely information disclosure [2] - The sustainability of government subsidies remains uncertain, and the company is monitoring potential new support projects or policies [3]

证券代码：301258 证券简称：富士莱 公告编号：2025-068 苏州富士莱医药股份有限公司 关于参加 2025 苏州上市公司投资者集体接待日活动 的公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、误导 性陈述或者重大遗漏。 为进一步加强与投资者的互动交流，苏州富士莱医药股份有限公司（以下简 称"公司"）将参加"2025 苏州上市公司投资者集体接待日"活动，现将相关 事项公告如下： 出席本次网上集体接待日的人员有：公司董事会秘书兼财务总监卞爱进先生； 证券事务代表吴晨钧先生。 2025 年 11 月 27 日 本次活动将采用网络远程的方式举行，投资者可登录"全景路演" （http://rs.p5w.net），或关注微信公众号：全景财经，或下载全景路演 APP，参 与本次互动交流，活动时间为 2025 年 12 月 2 日（星期二，15:30-17:00）。 届时公司将在线就投资者关心的问题，与投资者进行沟通与交流，欢迎广大 投资者踊跃参与！ 特此公告。 苏州富士莱医药股份有限公司 董事会 ...

证券代码：301258 证券简称：富士莱 公告编号：2025-067 苏州富士莱医药股份有限公司 2025 年第三次临时股东会决议公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、误导 性陈述或者重大遗漏。 特别提示： 1.本次股东会不存在否决议案的情形。 2.本次股东会不涉及变更以往股东会已通过的决议。 一、会议召开情况 （一）会议召开的时间 1、现场会议时间：2025 年 11 月 26 日下午 14:30。 2、网络投票时间：2025 年 11 月 26 日 （1）通过深圳证券交易所交易系统进行网络投票的时间为： 2025 年 11 月 26 日上午 9:15-9:25，9:30-11:30，下午 13:00-15:00； （2）通过深圳证券交易所互联网投票系统进行网络投票的时间为 2025 年 11 月 26 日 9:15-15:00。 （二）现场会议召开地点：江苏省常熟市新材料产业园海旺路 16 号 （三）股权登记日：2025 年 11 月 20 日 （四）会议召开方式：现场表决和网络表决相结合的方式。同一表决权只能 选择现场投票或网络投票表决方式中的一种，不能重复投票，同一 ...

上海兰迪（苏州）律师事务所 法律意见书 上海兰迪（苏州）律师事务所 关于苏州富士莱医药股份有限公司 2025 年第三次临时股东会的 法律意见书 地址：苏州市姑苏区人民路 3110 号国发大厦南楼 907 电话：0512-67872033 上海兰迪（苏州）律师事务所 法律意见书 上海兰迪（苏州）律师事务所 关于苏州富士莱医药股份有限公司 2025 年第三次临时股东会的 法律意见书 致：苏州富士莱医药股份有限公司 上海兰迪（苏州）律师事务所（以下简称"本所"）接受苏州富士莱医药股份有 限公司（以下简称"公司"）的委托，就贵公司召开的 2025 年第三次临时股东会 （以下简称"本次股东会"）进行见证并就相关事宜出具本法律意见书。 本所律师根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中华 人民共和国证券法》（以下简称"《证券法》"）、《上市公司股东会规则》（以下 简称"《股东会规则》"）、《深圳证券交易所上市公司股东会网络投票实施细则》 以及《苏州富士莱医药股份有限公司章程》（以下简称"《公司章程》"）等规定， 就本次股东会的召集和召开程序、召集人资格和出席会议人员资格、会议表决程序和 表决结果等相关事 ...

（文章来源：证券日报） 证券日报网讯富士莱11月25日在互动平台回答投资者提问时表示，公司与恒瑞医药的合作进展顺利，公 司期待以此为基础，未来拓展更多合作机会。 ...

Core Viewpoint - Fujifilm announced on November 25 that it has received the GMP compliance inspection result notification from the Jiangsu Provincial Drug Administration, confirming that its active pharmaceutical ingredient, Apatinib Mesylate, meets GMP standards, laying a solid foundation for future commercialization [1] Group 1 - The company has successfully passed the GMP compliance inspection for its raw material drug Apatinib Mesylate [1] - This compliance is crucial for the subsequent commercialization of the product [1]

Core Viewpoint - Fujilai plans to deepen its existing business layout in the coming year, actively seizing market opportunities through product structure optimization, cost reduction, efficiency enhancement, and steady market expansion to achieve sustainable development and stable performance improvement [1] Group 1 - The company aims to optimize its product structure [1] - The company is focused on cost reduction and efficiency enhancement [1] - The company intends to steadily expand its market presence [1]

Core Viewpoint - Fujifilm announced on November 25 that it is a major manufacturer of alpha-lipoic acid series products, alongside Tonghe Pharmaceutical, and expects a 5.47% year-on-year increase in the shipment volume of its core product, granular alpha-lipoic acid, in the first half of 2025 due to proactive market expansion strategies and flexible pricing policies [1]. Company Summary - Fujifilm is actively expanding its market presence and implementing flexible pricing strategies to enhance its product competitiveness [1]. - The company anticipates a growth in shipment volume of granular alpha-lipoic acid, indicating a positive outlook for its core product line [1]. Industry Summary - The alpha-lipoic acid market is characterized by significant competition, with Fujifilm and Tonghe Pharmaceutical being key players in the export segment [1]. - The expected growth in shipment volume reflects a broader trend of increasing demand for alpha-lipoic acid products in the market [1].

Core Points - Fujilai announced the completion of its share repurchase program as of November 20, 2025, having repurchased a total of 1,090,000 shares [1] - The repurchased shares represent 1.1890% of the company's total share capital [1]

Core Viewpoint - Fujilai (301258.SZ) has successfully completed a share repurchase program, acquiring 1,090,000 shares, which represents 1.1890% of the company's total share capital, in compliance with its established plan and relevant regulations [1] Summary by Categories Share Repurchase Details - The repurchase was conducted through the Shenzhen Stock Exchange's centralized bidding system [1] - The highest transaction price was 35.80 CNY per share, while the lowest was 33.88 CNY per share [1] - The total amount spent on the repurchase was 37,944,238.00 CNY, excluding transaction fees [1] Compliance and Financial Implications - The total funds used for the repurchase exceeded the lower limit set in the repurchase plan but did not surpass the upper limit [1] - The repurchase program has been fully implemented in accordance with the company's established plan and relevant legal requirements [1]